CARMAX INC

**Signal Note: Eventide Values-Based Fund Adds CarMax** This is notably an *auto retail* position, not a biotech holding—CarMax operates used vehicle dealerships with no direct pharma/biotech exposure. The $266K position (6,776 shares at ~$39/share) suggests either: (1) portfolio rebalancing toward non-biotech diversification, or (2) conviction on CarMax's operational/valuation metrics independent of Eventide's biotech mandate. Without confirmed values-alignment rationale from the fund, this appears tangential to typical biotech sector catalysts and warrants clarification on investment thesis.